Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer

NCT04580771 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04580771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04580771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 14, 2020
Completion date
March 8, 2027
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cervical squamous cell carcinoma, not otherwise specified, stage ib3 cervical cancer figo 2018, stage ii cervical cancer figo 2018, stage iia cervical cancer figo 2018, stage iia1 cervical cancer figo 2018, stage iia2 cervical cancer figo 2018, stage iib cervical cancer figo 2018, stage iii cervical cancer figo 2018, stage iiia cervical cancer figo 2018, stage iiib cervical cancer figo 2018, stage iiic cervical cancer figo 2018, stage iiic1 cervical cancer figo 2018, stage iiic2 cervical cancer figo 2018, stage iva cervical cancer figo 2018